Allogeneic
|
| | |
18
|
Sweden
|
allogeneic dendritic cell vaccine (ilixadencel)
|
Safety; immunological response activated against HCC
|
NCT01974661
|
[20]
|
Autologous
|

|
I/IIa
| |
8/12
|
China
|
autologous fixed HCC vaccine
|
Safety; recurrence delay for patients with HCC after operation
|
–
|
[21]
|
|
| | |
41
|
China
|
autologous fixed HCC vaccine
|
Safety; recurrence rates reduced and overall survival rates improved for patients with HCC after operation
|
–
|
[22]
|
|
| | |
8
|
USA
|
bi-shRNAfurin/GM-CSF incorporated autologous HCC cell vaccine
|
Safety; immunological response activated against HCC and overall survival prolonged
|
–
|
[23]
|
|
-
| | |
160
|
China
|
autologous DC-tumor vaccine
|
Safety; recurrence and metastasis rates for postoperative HCC patients reduced; survival rates improved
|
–
|
[24]
|
|
| | |
10
|
Japan
|
autologous tumor lysates pulsed DC vaccine
|
Safety; antitumor efficiency probably existed against PLC: delayed type hypersensitivity induced (7/10); tumor size shrinked (1/10); serum level of tumor marker decreased (2/10)
|
–
|
[25]
|
|

| | |
31
|
China
|
autologous tumor lysates pulsed DC vaccine
|
Safety; HCC patients’ survival better prolonged by boosters followed DCs therapy than single DCs vaccine itself
|
–
|
[26]
|
|
| | |
36
|
Japan
|
autologous tumor lysates pulsed DC vaccine
|
Survival for iCCA patients prolonged; prognosis improved
|
UMIN000005820
|
[27]
|